From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

doi:10.5306/wjco.v8.i1.37

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8235)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

869

WORD

398

HTML

4523

Tables (1-3)

317

Sum=6107

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

920

Download

1208

Sum=2128

Feb 10, 2017 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (46)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Feb 10, 2017; 8(1): 37-53
Published online Feb 10, 2017. doi: 10.5306/wjco.v8.i1.37

Table 3 Phase III randomized clinical trials currently ongoing with PD-1/PD-L1 axis blockade in advanced setting for solid tumors

Trial name/NCT	Cancer type	Immune checkpoint inhibitor	Arms	Treatment line	Primary endpoint	Expected primary completion date	No. of patients
STOP-GAP[15]	Melanoma	PD-1 inhibitor (any)	Intermittent vs continuous therapy	Any	OS	2025	550
NCT02752074[16]	Melanoma	Pembrolizumab	Pembrolizumab + epacadostat vs pembrolizumab + placebo	I line	PFS	2018	600
MASTERKEY-265[17]	Melanoma	Pembrolizumab	Pembrolizumab + talimogene laherparepvec vs pembrolizumab + placebo	I line	PFS	2018	660
KEYNOTE-048[82]	HNSCC	Pembrolizumab	Pembrolizumab vs CT¹ + pembrolizumab vs CT¹	I line	PFS	2018	780
KEYNOTE-040[38]	HNSCC	Pembrolizumab	Pembrolizumab vs methotrexate or docetaxel or cetuximab	From II line	OS	2017	466
KEYNOTE-204[39]	Hodgkin lymphoma	Pembrolizumab	Pembrolizumab vs brentuximab	From II line	PFS	2019	300
KEYNOTE-045[40]	Urothelial cancers	Pembrolizumab	Pembrolizumab vs paclitaxel, docetaxel or vinflunine	From II line	OS	2017²	470
NCT02811861[41]	Renal cell carcinoma	Pembrolizumab	Pembrolizumab + lenvatinib vs lenvatinib + everolimus vs sunitinib	I line	PFS	2020	735
KEYNOTE-426[102]	Renal cell carcinoma	Pembrolizumab	Pembrolizumab + axitinib vs sunitinib	I line	PFS, OS	2019	840
KEYNOTE-240[42]	HCC	Pembrolizumab	Pembrolizumab vs BSC	II line	PFS	2019	408
KEYNOTE-189[43]	NSqNSCLC	Pembrolizumab	Platinum and pemetrexed ± pembrolizumab	I line	PFS	2017	570
KEYNOTE-407[44]	SqNSCLC	Pembrolizumab	CT¹± pembrolizumab	I line	PFS	2018	560
KEYNOTE-042[45]	NSCLC PD-L1-positive	Pembrolizumab	Pembrolizumab vs platinum based CT¹	I line	OS	2018	1240
KEYNOTE-010[46]	NSCLC	Pembrolizumab	Pembrolizumab vs docetaxel	From II line	OS	2019	1034
KEYNOTE-119[47]	Triple negative breast cancer	Pembrolizumab	Pembrolizumab vs monochemotherapy	II-III line	PFS	2017	600
KEYNOTE-355[48]	Triple negative breast cancer	Pembrolizumab	CT¹ + pembrolizumab vs CT¹ + placebo	I line	PFS	2019	858
KEYNOTE-177[49]	MSI-H or dMMR colorectal carcinoma	Pembrolizumab	Pembrolizumab vs CT¹	I line	PFS	2019	270
KEYNOTE-181[50]	Esophageal/esophago-gastric junction carcinoma	Pembrolizumab	Pembrolizumab vs monochemotherapy¹	II line	PFS	2018	600
KEYNOTE-061[51]	Esophageal/esophago-gastric junction adenocarcinoma	Pembrolizumab	Pembrolizumab vs paclitaxel	II line	PFS	2017	720
KEYNOTE-062[52]	Esophageal/esophago-gastric junction carcinoma	Pembrolizumab	Pembrolizumab vs CT¹ + pembrolizumab vs CT¹	I line	PFS	2019	750
JAVELIN Ovarian 200[53]	Ovarian cancer (platinum resistant)	Avelumab	Avelumab vs avelumab plus PLD vs PLD	From II line	OS	2018	550
JAVELIN Ovarian 100[54]	Ovarian cancer	Avelumab	CT¹vs CT¹ followed by avelumab maintenance vs CT¹ + avelumab followed by avelumab maintenance	I line	PFS	2019	951
JAVELIN Renal 101[55]	Renal cell cancer	Avelumab	Avelumab with axitinib vs sunitinib	I line	PFS	2018	583
JAVELIN Bladder 100[56]	Urothelial cancer	Avelumab	Avelumab vs BSC (maintenance after CT¹)	I line maintenance	OS	2019	668
JAVELIN Gastric 100[57]	Adenocarcinoma of the stomach or of the gastro-esophageal junction	Avelumab	CT¹ continuation vs avelumab in maintenance after CT¹	I line	OS	2018	666
JAVELIN Gastric 300[58]	Adenocarcinoma of the stomach or of the gastro-esophageal junction	Avelumab	Avelumab + BSC vs CT¹ + BSC vs BSC	III line	OS	2017	330
JAVELIN Lung 100[59]	NSCLC (PD-L1 positive)	Avelumab	Avelumab vs platinum based CT¹	I line	PFS	2017	420
JAVELIN Lung 200[60]	NSCLC (PD-L1 positive)	Avelumab	Avelumab vs docetaxel	From II line	OS	2017	650
OAK[61]	NSqNSCLC	Atezolizumab	Atezolizumab vs docetaxel	From II line	OS	2017	1225
IMvigor211[62]	Bladder cancer	Atezolizumab	Atezolizumab vs monochemotherapy	II line	OS	2017	932
IMvigor130[63]	Urothelial carcinoma (ineligible for cisplatin)	Atezolizumab	Atezolizumab + CT¹vs placebo + CT¹	I line	PFS	2019	435
IMpower110[64]	NSqNSCLC	Atezolizumab	Atezolizumab vs platin + pemetrexed	I line	PFS	2019	570
IMpower111[65]	SqNSCLC	Atezolizumab	Atezolizumab vs gemcitabine + platin	I line	PFS	2017	ND
IMpower131[66]	SqNSCLC	Atezolizumab	Atezolizumab + nab-paclitaxel + carboplatin vs atezolizumab + paclitaxel + carboplatin vs nab-paclitaxel + carboplatin	I line	PFS	2023	1200
IMpower210[67]	NSCLC	Atezolizumab	Atezolizumab vs docetaxel	II line	OS	2019	563
IMpower130[68]	NSqNSCLC	Atezolizumab	Atezolizumab + nab-paclitaxel + carboplatin vs nab-paclitaxel + carboplatin	I line	PFS	2019	550
IMpower150[69]	NSqNSCLC	Atezolizumab	Atezolizumab + carboplatin + paclitaxel ± bevacizumab vs carboplatin + paclitaxel + bevacizumab	I line	PFS	2017	1200
IMpassion130[70]	Triple negative breast cancer	Atezolizumab	Atezolizumab + nab-paclitaxel vs placebo + nab paclitaxel	I line	PFS	2020	900
IMmotion151[71]	Renal cell carcinoma	Atezolizumab	Atezolizumab + bevacizumab vs sunitinib	I line	PFS	2020	900
IMpower133[72]	SCLC	Atezolizumab	Carboplatin and etoposide ± atezolizumab	I line	OS	2019	400
NCT02788279[73]	Colorectal carcinoma	Atezolizumab	Atezolizumab + cobimetinib vs atezolizumab vs regorafenib	From III line	OS	2019	360
KESTREL[74]	HNSCC	Durvalumab	Durvalumab vs durvalumab + tremelimumab vs SOC	I line	PFS	2017	628
MYSTIC[75]	NSCLC	Durvalumab	Durvalumab vs durvalumab + tremelimumab vs SOC	I line	PFS	2017	1092
Danube[76]	Bladder cancer	Durvalumab	Durvalumab vs durvalumab + tremelimumab vs SOC¹	I line	PFS	2017	525
Lung-MAP[77]	SqNSCLC (biomarker-targeted)	Durvalumab, nivolumab	Docetaxel vs durvalumab vs erlotinib vs AZD4547 vs ipilimumab vs palbociclib vs rilotumumab vs taselisib	Any	PFS	2022	10000
CAURAL[78]	NSCLC T790M mutation positive	Durvalumab	AZD9291 + durvalumab vs AZD9291	II-III line	PFS	2018	350
NCT02369874[79]	HNSCC	Durvalumab	Durvalumab vs durvalumab + tremelimumab vs SOC¹	II line	OS	2018	720
NEPTUNE[80]	NSCLC	Durvalumab	Durvalumab + tremelimumab vs SOC¹	I line	OS	2018	800
ARCTIC[81]	NSCLC	Durvalumab	Durvalumab vs durvalumab + tremelimumab vs SOC¹	II-III line	OS	2016	730
NCT02224781[18]	Melanoma BRAFV600 mutated	Nivolumab	Dabrafenib + trametinib followed by ipilimumab + nivolumab vs ipilimumab + nivolumab followed by dabrafenib + trametinib	I line	OS	2019	300
NIBIT-M2[14]	Melanoma brain metastases	Nivolumab	Fotemustine vs ipilimumab + fotemustine vs ipilimumab + nivolumab	Any	OS	2018	168
CheckMate 026[37]	NSCLC PD-L1 positive (all)	Nivolumab	Nivolumab vs CT¹	I line	PFS	2016²	535
CheckMate 651[83]	H&N SCC	Nivolumab	Nivolumab + ipilimumab vs platinum + fluorouracil + cetuximab	I line	OS	2020	490
CheckMate 459[84]	HCC	Nivolumab	Nivolumab vs sorafenib	I line	TTP	2017	726
NCT02267343[85]	Gastric cancer	Nivolumab	Nivolumab vs placebo	From II line	OS	2017	480
NCT02569242[86]	Esophageal cancer	Nivolumab	Nivolumab vs docetaxel/paclitaxel	From II line	OS	2019	390
CheckMate 214[87]	Renal cell carcinoma	Nivolumab	Nivolumab + ipilimumab vs sunitinib	I line	PFS	2019	1070
CheckMate 143[88]	Glioblastoma	Nivolumab	Nivolumab vs bevacizumab	II line	OS	2017	440
CheckMate 141[89]	H&N SCC	Nivolumab	Nivolumab vs cetuximab/methotrexate/docetaxel monotherapy	Any	OS	2018	360
CheckMate 227[90]	NSCLC	Nivolumab	Nivolumab vs nivolumab + ipilimumab vs nivolumab + platinum doublet CT¹	I line	OS	2018	1980
CheckMate 451[91]	SCLC	Nivolumab	Nivolumab vs nivolumab + ipilimumab vs placebo after platinum based CT¹	Maintenance after I line	OS	2018	810
CheckMate 498[92]	Glioblastoma (unmethylated MGMT)	Nivolumab	Nivolumab + RT vs temozolomide + RT	I line	PFS	2019	550
CheckMate 331[93]	SCLC	Nivolumab	Nivolumab vs topotecan/amrubicin	II line	OS	2018	480
CheckMate 078[94]	NSCLC	Nivolumab	Nivolumab vs docetaxel	From II line	OS	2018	500
NCT02339571[95]	Melanoma	Nivolumab	Nivolumab + ipilimumab ± sargramostim	I line	OS	2021	400
CheckMate 401[96]	Melanoma	Nivolumab	Nivolumab + ipilimumab vs nivolumab	I line	OS	2021	615

¹According to the standard of care and basing on the choice of the investigator;

²The trial has results but it is still unpublished. OS: Overall survival; PFS: Progression free survival; HNSCC: Head and neck squamous cell carcinoma; HCC: Hepatocarcinoma; NSqNSCLC: Non-squamous non-small cell lung cancer; SqNSCLC: Squamous non-small cell lung cancer; CT: Chemotherapy; NSCLC: Non-small cell lung cancer; MSI-H: High microsatellite instability; dMMR: Deficient mismatch repair; PLD: Pegylated liposomal doxorubicin; SCLC: Small cell lung cancer; TTP: Time to progression; ORR: Objective response rate.

Citation: Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol 2017; 8(1): 37-53
URL: https://www.wjgnet.com/2218-4333/full/v8/i1/37.htm
DOI: https://dx.doi.org/10.5306/wjco.v8.i1.37